Study of the Effects of Atorvastatin for Heart Problems that may Occur in Subjects Treated with Chemotherapy

What we are studying

The purpose of this research study is to see if Atorvastatin (generic for Lipitor) 40 mg by mouth daily decreases the chance of developing heart problems in women receiving anthracycline based chemotherapy for breast cancer.

Who is Eligible

  • Genders:
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 30+

Eligibility Criteria

  • Newly diagnosed Stage I-III female breast cancer (including inflammatory and newly diagnosed recurrent breast cancer)
  • Scheduled to receive adjuvant or neoadjuvant chemotherapy with an Anthracycline (doxorubicin or epirubicin)
  • Prior chemotherapy regimen not containing anthracyclines is allowed
  • Able to hold breathe for 10 seconds
  • Prior cancers allowed if no evidence of disease in last 5 years

What is involved

  • 2 MRI exams of the heart
  • 3 Fasting blood samples and biomarker blood samples
  • Memory and Thinking Ability Testing
  • Quality of Life Questionnaires
  • 2 Telephone calls



Contact Information

Study Coordinator
Robin Rosdhal
[email protected]
(336) 713-6519
Principal Investigator
Dr. Greg Hundley

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.